The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment

The Research Progress of Trastuzumab-Induced Cardiotoxicity in HER-2-Positive Breast Cancer Treatment

In recent years, the incidence of breast cancer has been increasing on an annual basis. Human epidermal growth factor receptor-2 (HER-2) is overexpressed in 15-20% human breast cancers, which is associated with poor prognosis and a high recurrence rate. Trastuzumab is the first humanized monoclonal...

Full description

Bibliographic Details
Main Authors: Mengmeng Lin, Weiping Xiong, Shiyuan Wang, Yingying Li, Chunying Hou, Chunyu Li, Guohui Li
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-01-01
Series:Frontiers in Cardiovascular Medicine
Subjects:
trastuzumab
cardiotoxicity
breast cancer
adverse reaction
rational drug use
Online Access:https://www.frontiersin.org/articles/10.3389/fcvm.2021.821663/full

Internet

https://www.frontiersin.org/articles/10.3389/fcvm.2021.821663/full

Similar Items